NCT04662294

CD 70 CAR T for Patients With CD70 Positive Malignant Hematologic Diseases

Clinical Trial for the Safety and Efficacy of CD 70 CAR T for Patients With CD70 Positive Malignant Hematologic Diseases

• Status: Recruiting
• Phase: EARLY_Phase 1
• Study type: Interventional
• Enrollment: 108 (estimated)
• Sponsor: Zhejiang University · Academic / Other
• Sex: All
• Age: —
• Healthy volunteers: Not accepted

Summary

A Study of CD 70 CAR T for patients with CD70 positive malignant hematologic diseases

Detailed description

This is a single arm, open-label, single-center study. This study is indicated for CD 70 CAR T for patients with CD70 positive malignant hematologic diseases. The selections of dose levels and the number of subjects are based on clinical trials of similar foreign products. 108 patients will be enrolled. Primary objective is to explore the safety,main consideration is dose-related safety.

Conditions

• Acute Myeloid Leukemia
• Non-hodgkin's Lymphoma
• Multiple Myeloma

Interventions

Type	Name	Description
BIOLOGICAL	CD70 CAR T-cells	Each subject receive CD70 CAR T-cells by intravenous infusion

Timeline

• Start date: 2021-11-18
• Primary completion: 2024-01-15
• Completion: 2027-01-15
• First posted: 2020-12-10
• Last updated: 2021-11-04

Locations

1 site across 1 country: China